Latest from Perlmutter Cancer Center at NYU Langone

Theodore H. Welling, MD, discusses the expanding role of surgery in hepatobiliary neoplasms.
Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses global vaccination and screening for cervical cancer.
 
Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses the Precision Promise trial for patients with metastastic pancreatic cancer.
 
Diane M. Simeone, MD, discusses the molecular complexities of pancreatic cancer, some of the commonly identified mutations, and ongoing clinical trial efforts that may be game changing for the field.
Paul E. Oberstein, MD, discusses incorporating novel agents and sequencing approaches in advanced pancreatic neoplasms.
Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses cervical cancer disparities in low-income countries.
Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the impact of the combination of durvalumab (Imfinzi) plus tremelimumab in metastatic bladder cancer.
Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses the importance of mutational analysis in the treatment of patients with pancreatic cancer.
Publication Bottom Border
Border Publication
x